Novacyt (PA:ALNOV) — Market Cap & Net Worth
Market Cap & Net Worth: Novacyt (ALNOV)
Novacyt (PA:ALNOV) has a market capitalization of $26.46 Million (€22.64 Million) as of May 4, 2026. Listed on the PA stock exchange, this France-based company holds position #24136 globally and #394 in its home market, demonstrating a -13.03% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Novacyt's stock price €0.32 by its total outstanding shares 70626248 (70.63 Million). Analyse cash efficiency ratio of Novacyt to see how efficiently the company converts income to cash.
Novacyt Market Cap History: 2015 to 2026
Novacyt's market capitalization history from 2015 to 2026. Data shows change from $251.84 Million to $26.46 Million (-20.45% CAGR).
Index Memberships
Novacyt is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
CAC PME
CAPME
|
$35.32 Billion | 0.07% | #25 of 34 |
Weight: Novacyt's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Novacyt Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Novacyt's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.53x
Novacyt's market cap is 2.53 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $251.84 Million | $6.56 Million | -$10.26 Million | 38.38x | N/A |
| 2016 | $92.48 Million | $9.44 Million | -$4.87 Million | 9.80x | N/A |
| 2017 | $56.97 Million | $13.28 Million | -$4.83 Million | 4.29x | N/A |
| 2018 | $32.04 Million | $12.37 Million | -$4.27 Million | 2.59x | N/A |
| 2019 | $13.95 Million | $11.18 Million | -$3.33 Million | 1.25x | N/A |
| 2020 | $809.18 Million | $277.20 Million | $132.42 Million | 2.92x | 6.11x |
| 2021 | $361.65 Million | $95.78 Million | -$9.73 Million | 3.78x | N/A |
| 2022 | $101.52 Million | $21.04 Million | -$22.20 Million | 4.83x | N/A |
| 2023 | $58.87 Million | $11.58 Million | -$28.29 Million | 5.08x | N/A |
| 2024 | $49.71 Million | $19.63 Million | -$41.76 Million | 2.53x | N/A |
Competitor Companies of ALNOV by Market Capitalization
Companies near Novacyt in the global market cap rankings as of May 4, 2026.
Key companies related to Novacyt by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #141 globally with a market cap of $155.56 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #208 globally with a market cap of $112.79 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #230 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (NYSE:MDT): Ranked #236 globally with a market cap of $102.56 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #141 | Abbott Laboratories | NYSE:ABT | $155.56 Billion | $89.46 |
| #208 | Stryker Corporation | NYSE:SYK | $112.79 Billion | $294.73 |
| #230 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #236 | Medtronic PLC | NYSE:MDT | $102.56 Billion | $80.00 |
Novacyt Historical Marketcap From 2015 to 2026
Between 2015 and today, Novacyt's market cap moved from $251.84 Million to $ 26.46 Million, with a yearly change of -20.45%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €26.46 Million | -18.03% |
| 2025 | €32.28 Million | -35.05% |
| 2024 | €49.71 Million | -15.57% |
| 2023 | €58.87 Million | -42.01% |
| 2022 | €101.52 Million | -71.93% |
| 2021 | €361.65 Million | -55.31% |
| 2020 | €809.18 Million | +5698.82% |
| 2019 | €13.95 Million | -56.44% |
| 2018 | €32.04 Million | -43.77% |
| 2017 | €56.97 Million | -38.39% |
| 2016 | €92.48 Million | -63.28% |
| 2015 | €251.84 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Novacyt was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $26.46 Million USD |
| MoneyControl | $26.46 Million USD |
| MarketWatch | $26.46 Million USD |
| marketcap.company | $26.46 Million USD |
| Reuters | $26.46 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Novacyt
Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer Design segments. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive h… Read more